New Ruling Reinforces Flexibility in 340B Administration—And Strengthens the Push for Innovative, Patient-Centered Models In…
Alex CullorJune 17, 2025
A Strategic Path Forward for CBOs Serving Individuals Living with HIV and Hepatitis C Community-based…
Alex CullorJune 10, 2025
A Sustainable Path Forward for Providers and At-Risk Communities Federal budget cuts are threatening the…
Alex CullorJune 5, 2025
Landmark Ruling Reinforces Safeguards for Safety-Net Providers Amid Pharmaceutical Industry Challenges In a significant development…
Alex CullorMay 27, 2025
HRSA’s 340B Rebate Ruling: A Win for Safety-Net Providers and Patients On May 16, 2025,…
Alex CullorMay 19, 2025
In the current political landscape, debates around drug pricing, tax policy, and entitlement reform are…
Alex CullorMay 14, 2025
How Clarifying 340B Duplicate Discount Policies Can Strengthen Patient Access and Provider Sustainability The 340B…
Alex CullorApril 9, 2025
The 340B Drug Pricing Program is facing unprecedented pressure. A growing number of pharmaceutical manufacturers…
Alex CullorMarch 26, 2025
